Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 10/20 | 0.41 |
| ▸ | TACR2 | P21452 | 9/20 | 0.41 |
| ▸ | TAC3 | Q9UHF0 | 3/20 | 0.41 |
| ▸ | TACR3 | P29371 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | SPTLC2 | O15270 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153692 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3TACR1TACR2 | |
| SCHEMBL1970998 | 0.86 | PDE4B (0.44) | SLC6A2SLC6A4SLC6A3TACR1TACR2 | |
| SCHEMBL30693130 | 0.86 | PDE4B (0.44) | SLC6A2SLC6A4SLC6A3TACR1TACR2 | |
| SCHEMBL4153226 | 0.84 | TACR2 (0.51) | TACR1TACR2TAC3TACR3SPTLC2 | |
| SCHEMBL19893253 | 0.83 | KDM1A (0.50) | TACR1SPTLC2 | |
| SCHEMBL4151135 | 0.83 | TACR1 (0.51) | TACR1TACR2TAC3TACR3SPTLC2 | |
| SCHEMBL4151130 | 0.83 | TACR1 (0.51) | TACR1TACR2TAC3TACR3SPTLC2 | |
| SCHEMBL4149557 | 0.83 | TACR1 (0.51) | TACR1TACR2TAC3TACR3SPTLC2 | |
| SCHEMBL4157136 | 0.82 | SSTR3 (0.49) | TACR1TACR2SPTLC2 | |
| SCHEMBL4157133 | 0.82 | SSTR3 (0.49) | TACR1TACR2SPTLC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | SLC6A2 241/4885SLC6A4 271/4885SLC6A3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.